Nivolumab/pembrolizumabTuberculosis: 2 case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1742卷 / 1期

关键词：

D O I：

10.1007/s40278-019-58634-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：176 / 176

相关论文

共 50 条

[31] Nivolumab IgA nephropathy: case report
Reactions Weekly, 2020, 1812 (1) : 210 - 210
[32] Nivolumab/lomustineAplastic anaemia: case report
Reactions Weekly, 2019, 1734 (1) : 378 - 378
[33] Nivolumab/sunitinibColitis and diarrhoea: case report
Reactions Weekly, 2020, 1795 (1) : 211 - 211
[34] Ipilimumab/nivolumab/pembrolizumabPneumonitis: case report
Reactions Weekly, 2018, 1713 (1) : 204 - 204
[35] Nivolumab/prednisoloneVarious toxicities: case report
Reactions Weekly, 2022, 1893 (1) : 266 - 266
[36] Nivolumab/PembrolizumabBullous pemphigoid: case report
Reactions Weekly, 2017, 1671 (1) : 312 - 312
[37] Nivolumab/sunitinibVarious toxicities: case report
Reactions Weekly, 2022, 1887 (1) : 536 - 536
[38] Nivolumab/TozinameranSweet syndrome: case report
Reactions Weekly, 2025, 2045 (1) : 330 - 330
[39] Nivolumab/pazopanibHepatitis and neuropathy: case report
Reactions Weekly, 2020, 1796 (1) : 189 - 189
[40] Nivolumab/temsirolimusVarious toxicities: case report
Reactions Weekly, 2022, 1919 (1) : 460 - 460

← 1 2 3 4 5 →